Does NSAID use modify cognitive trajectories in the elderly? The Cache County study

K. M. Hayden, Peter P Zandi, A. S. Khachaturian, C. A. Szekely, M. Fotuhi, M. C. Norton, J. T. Tschanz, C. F. Pieper, C. Corcoran, Constantine G Lyketsos, John C.S. Breitner, K. A. Welsh-Bohmer

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Epidemiologic studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) may be useful for the prevention of Alzheimer disease (AD). By contrast, clinical trials have not supported NSAID use to delay or treat AD. Few studies have evaluated cognitive trajectories of NSAID users over time. METHODS: Residents of Cache County, UT, aged 65 or older on January 1, 1995, were invited to participate in the study. At baseline, participants provided a detailed inventory of their medications and completed a revised Modified Mini-Mental State Examination (3MS). Participants (n = 3,383) who were cognitively normal at baseline were re-examined after 3 and 8 years. The association between NSAID use and 3MS scores over time was estimated using random effects modeling. RESULTS: Associations depended upon when NSAIDs were started and APOE genotype. In participants who started NSAID use prior to age 65, those with no APOE ε4 alleles performed similarly to nonusers (a difference of 0.10 points per year; p = 0.19), while those with one or more ε4 allele(s) showed more protection (0.40 points per year; p = 0.0005). Among participants who first used NSAIDs at or after age 65, those with one or more ε4 alleles had higher baseline scores (0.95 points; p = 0.03) but did not show subsequent difference in change in score over time (0.06 points per year; p = 0.56). Those without an ε4 allele who started NSAID use after age 65 showed greater decline than nonusers (-0.16 points per year; p = 0.02). CONCLUSIONS: Nonsteroidal anti-inflammatory drug use may help to prevent cognitive decline in older adults if started in midlife rather than late life. This effect may be more notable in those who have one or more APOE ε4 alleles.

Original languageEnglish (US)
Pages (from-to)275-282
Number of pages8
JournalNeurology
Volume69
Issue number3
DOIs
StatePublished - Jul 2007

Fingerprint

Anti-Inflammatory Agents
Pharmaceutical Preparations
Alleles
Alzheimer Disease
Drug Users
Epidemiologic Studies
Genotype
Clinical Trials
Equipment and Supplies

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., ... Welsh-Bohmer, K. A. (2007). Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology, 69(3), 275-282. https://doi.org/10.1212/01.wnl.0000265223.25679.2a

Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. / Hayden, K. M.; Zandi, Peter P; Khachaturian, A. S.; Szekely, C. A.; Fotuhi, M.; Norton, M. C.; Tschanz, J. T.; Pieper, C. F.; Corcoran, C.; Lyketsos, Constantine G; Breitner, John C.S.; Welsh-Bohmer, K. A.

In: Neurology, Vol. 69, No. 3, 07.2007, p. 275-282.

Research output: Contribution to journalArticle

Hayden, KM, Zandi, PP, Khachaturian, AS, Szekely, CA, Fotuhi, M, Norton, MC, Tschanz, JT, Pieper, CF, Corcoran, C, Lyketsos, CG, Breitner, JCS & Welsh-Bohmer, KA 2007, 'Does NSAID use modify cognitive trajectories in the elderly? The Cache County study', Neurology, vol. 69, no. 3, pp. 275-282. https://doi.org/10.1212/01.wnl.0000265223.25679.2a
Hayden, K. M. ; Zandi, Peter P ; Khachaturian, A. S. ; Szekely, C. A. ; Fotuhi, M. ; Norton, M. C. ; Tschanz, J. T. ; Pieper, C. F. ; Corcoran, C. ; Lyketsos, Constantine G ; Breitner, John C.S. ; Welsh-Bohmer, K. A. / Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. In: Neurology. 2007 ; Vol. 69, No. 3. pp. 275-282.
@article{02e5f05742444245aa1433a6e80709d3,
title = "Does NSAID use modify cognitive trajectories in the elderly? The Cache County study",
abstract = "BACKGROUND: Epidemiologic studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) may be useful for the prevention of Alzheimer disease (AD). By contrast, clinical trials have not supported NSAID use to delay or treat AD. Few studies have evaluated cognitive trajectories of NSAID users over time. METHODS: Residents of Cache County, UT, aged 65 or older on January 1, 1995, were invited to participate in the study. At baseline, participants provided a detailed inventory of their medications and completed a revised Modified Mini-Mental State Examination (3MS). Participants (n = 3,383) who were cognitively normal at baseline were re-examined after 3 and 8 years. The association between NSAID use and 3MS scores over time was estimated using random effects modeling. RESULTS: Associations depended upon when NSAIDs were started and APOE genotype. In participants who started NSAID use prior to age 65, those with no APOE ε4 alleles performed similarly to nonusers (a difference of 0.10 points per year; p = 0.19), while those with one or more ε4 allele(s) showed more protection (0.40 points per year; p = 0.0005). Among participants who first used NSAIDs at or after age 65, those with one or more ε4 alleles had higher baseline scores (0.95 points; p = 0.03) but did not show subsequent difference in change in score over time (0.06 points per year; p = 0.56). Those without an ε4 allele who started NSAID use after age 65 showed greater decline than nonusers (-0.16 points per year; p = 0.02). CONCLUSIONS: Nonsteroidal anti-inflammatory drug use may help to prevent cognitive decline in older adults if started in midlife rather than late life. This effect may be more notable in those who have one or more APOE ε4 alleles.",
author = "Hayden, {K. M.} and Zandi, {Peter P} and Khachaturian, {A. S.} and Szekely, {C. A.} and M. Fotuhi and Norton, {M. C.} and Tschanz, {J. T.} and Pieper, {C. F.} and C. Corcoran and Lyketsos, {Constantine G} and Breitner, {John C.S.} and Welsh-Bohmer, {K. A.}",
year = "2007",
month = "7",
doi = "10.1212/01.wnl.0000265223.25679.2a",
language = "English (US)",
volume = "69",
pages = "275--282",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Does NSAID use modify cognitive trajectories in the elderly? The Cache County study

AU - Hayden, K. M.

AU - Zandi, Peter P

AU - Khachaturian, A. S.

AU - Szekely, C. A.

AU - Fotuhi, M.

AU - Norton, M. C.

AU - Tschanz, J. T.

AU - Pieper, C. F.

AU - Corcoran, C.

AU - Lyketsos, Constantine G

AU - Breitner, John C.S.

AU - Welsh-Bohmer, K. A.

PY - 2007/7

Y1 - 2007/7

N2 - BACKGROUND: Epidemiologic studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) may be useful for the prevention of Alzheimer disease (AD). By contrast, clinical trials have not supported NSAID use to delay or treat AD. Few studies have evaluated cognitive trajectories of NSAID users over time. METHODS: Residents of Cache County, UT, aged 65 or older on January 1, 1995, were invited to participate in the study. At baseline, participants provided a detailed inventory of their medications and completed a revised Modified Mini-Mental State Examination (3MS). Participants (n = 3,383) who were cognitively normal at baseline were re-examined after 3 and 8 years. The association between NSAID use and 3MS scores over time was estimated using random effects modeling. RESULTS: Associations depended upon when NSAIDs were started and APOE genotype. In participants who started NSAID use prior to age 65, those with no APOE ε4 alleles performed similarly to nonusers (a difference of 0.10 points per year; p = 0.19), while those with one or more ε4 allele(s) showed more protection (0.40 points per year; p = 0.0005). Among participants who first used NSAIDs at or after age 65, those with one or more ε4 alleles had higher baseline scores (0.95 points; p = 0.03) but did not show subsequent difference in change in score over time (0.06 points per year; p = 0.56). Those without an ε4 allele who started NSAID use after age 65 showed greater decline than nonusers (-0.16 points per year; p = 0.02). CONCLUSIONS: Nonsteroidal anti-inflammatory drug use may help to prevent cognitive decline in older adults if started in midlife rather than late life. This effect may be more notable in those who have one or more APOE ε4 alleles.

AB - BACKGROUND: Epidemiologic studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) may be useful for the prevention of Alzheimer disease (AD). By contrast, clinical trials have not supported NSAID use to delay or treat AD. Few studies have evaluated cognitive trajectories of NSAID users over time. METHODS: Residents of Cache County, UT, aged 65 or older on January 1, 1995, were invited to participate in the study. At baseline, participants provided a detailed inventory of their medications and completed a revised Modified Mini-Mental State Examination (3MS). Participants (n = 3,383) who were cognitively normal at baseline were re-examined after 3 and 8 years. The association between NSAID use and 3MS scores over time was estimated using random effects modeling. RESULTS: Associations depended upon when NSAIDs were started and APOE genotype. In participants who started NSAID use prior to age 65, those with no APOE ε4 alleles performed similarly to nonusers (a difference of 0.10 points per year; p = 0.19), while those with one or more ε4 allele(s) showed more protection (0.40 points per year; p = 0.0005). Among participants who first used NSAIDs at or after age 65, those with one or more ε4 alleles had higher baseline scores (0.95 points; p = 0.03) but did not show subsequent difference in change in score over time (0.06 points per year; p = 0.56). Those without an ε4 allele who started NSAID use after age 65 showed greater decline than nonusers (-0.16 points per year; p = 0.02). CONCLUSIONS: Nonsteroidal anti-inflammatory drug use may help to prevent cognitive decline in older adults if started in midlife rather than late life. This effect may be more notable in those who have one or more APOE ε4 alleles.

UR - http://www.scopus.com/inward/record.url?scp=34547590424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547590424&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000265223.25679.2a

DO - 10.1212/01.wnl.0000265223.25679.2a

M3 - Article

C2 - 17636065

AN - SCOPUS:34547590424

VL - 69

SP - 275

EP - 282

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -